FILING ANALYSIS · MONDAY, NOVEMBER 16
AEON Biopharma, Inc. AEON — 8-K: Results of Operations and Financial Condition
neutral
AEON Biopharma received FDA Type 2b feedback and submitted an IND for a comparative CMAP pharmacodynamic study, with $6.2 million in milestone warrant proceeds providing additional capital, but no quantified surprise in earnings or guidance was reported
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →